Uncategorized

2026 will mark the fourth consecutive year of substantial health benefit cost growth, signaling “mounting pressure on employers’ healthcare budgets.”

The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window slammed shut.

The board of directors called for Derick Apt to resign, amid allegations he improperly accepted a “series of high value” gifts.

The nonpartisan scorekeeper’s new report reinforces longstanding concerns about the 340B drug discount program, including that it incentivizes behaviors that increase health costs for federal and private payers.

BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.

The prosecutor’s office opened an investigation in June, with charges including aggravated fraud and failure to report incidents that pose serious health risks.

The high court granted an expedited review of an appellate court finding that the president’s sweeping tariffs were illegal.

As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort, BioSpace looks back on the Danish pharma company’s rise.

Hospital finances have been generally strong this year, but the future is precarious as expenses — including non-labor costs — rise, according to an analysis by Kaufman Hall.

These 27 markets, comprising countries across Asia, Europe and South America, together contributed some 12% of Lundbeck’s earnings in 2024.